FAM181A Activators
FAM181A may be activated by various chemical compounds through distinct signaling pathways. Certain small molecules can directly stimulate adenylyl cyclase or inhibit phosphodiesterases, leading to elevated intracellular cAMP levels, thus potentially activating FAM181A through cAMP-dependent protein kinase A (PKA) signaling. In this context, adrenergic receptor agonists and prostaglandin E2 analogs contribute to this increase in cAMP, which could subsequently influence the activity of FAM181A. Additionally, the inhibition of glycogen synthase kinase-3 and the stabilization of Wnt signaling pathway components might indirectly modify FAM181A activity through downstream signaling effectors.
Moreover, the modulation of intracellular calcium levels through G-protein coupled receptor agonists provides another potential route for altering FAM181A activity. Nitric oxide donors and their precursors stimulate the production of nitric oxide, which activates soluble guanylate cyclase, thereby increasing cGMP levels. The subsequent activation of cGMP-dependent protein kinases could impact FAM181A indirectly. Furthermore, specific phosphodiesterase inhibitors focus on maintaining elevated levels of cGMP, amplifying signaling cascades that may indirectly lead to the functional activation of FAM181A.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-selective phosphodiesterase inhibitor that prevents cAMP breakdown, potentially enhancing pathways that lead to FAM181A activation through sustained cAMP signaling. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Selective phosphodiesterase-4 inhibitor that raises cAMP levels specifically, possibly facilitating FAM181A activation via cAMP-dependent protein kinase A (PKA) signaling. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Acts on adrenergic receptors, leading to increased intracellular cAMP, which may indirectly activate FAM181A by promoting PKA-mediated signaling pathways. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Binds to prostaglandin E2 receptors, which can increase intracellular cAMP, potentially leading to the activation of FAM181A through PKA-dependent mechanisms. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Activates G-protein coupled receptors which can increase intracellular calcium levels, possibly affecting FAM181A activity through calcium-dependent signaling mechanisms. | ||||||
L-Arginine | 74-79-3 | sc-391657B sc-391657 sc-391657A sc-391657C sc-391657D | 5 g 25 g 100 g 500 g 1 kg | $20.00 $31.00 $61.00 $219.00 $352.00 | 2 | |
Precursor of nitric oxide, which can lead to activation of soluble guanylate cyclase and subsequent increases in cGMP, possibly impacting FAM181A activity indirectly. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Phosphodiesterase 5 inhibitor that prevents cGMP breakdown, potentially enhancing signaling pathways that could lead to FAM181A activation. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Inhibits glycogen synthase kinase-3, which may lead to the activation of Wnt signaling pathway indirectly influencing FAM181A activity through downstream effectors. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Cell-permeable cAMP analog that directly activates PKA, potentially leading to the activation of FAM181A through PKA-dependent signaling pathways. | ||||||